Are booster immunisations needed for lifelong hepatitis B immunity?

Lancet

Volumn 355, Issue 9203, 2000, Pages 561-565

  Kane, M ^a   Banatvala, J ^a   Da Villa, G ^a   Esteban, R ^a   Franco, E ^a   Goudeau, A ^a   Grob, P ^a   Jilg, W ^a   Rizzetto, M ^a   Van Damme, P ^a   Van Hattum, J ^a   West, D ^a   Zuckerman, J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; DISEASE CARRIER; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; LYMPHOCYTE TRANSFORMATION TEST; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0001566476     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)07239-6     Document Type: Note

References (38)

1. World Health Organization. WHO expanded programme on immunisation. Report of 14th Global Advisory Group (Antalya, Turkey, Oct 14-18, 1991). Geneva: WHO, 1991: WHO/EPI/GEN/92.1.
2. Kane M. Status of hepatitis B immunization programmes in 1998. Vaccine. 16(suppl):1998;S104-108.
3. Recommendations of the Immunisation Practices Advisory Committee. Recommendations for protection against viral hepatitis. MMWR. 34:1985;329-335.
4. Immunisation against hepatitis B. Lancet. i:1988;875-876.
5. Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine: final report. 1992;WHO, Geneva.
6. Salisbury D.M., Begg N.T. Immunisation against infectious disease. 1996;95-408 HM Stationery Office, London.
7. Jilg W., Schmidt M., Zachoval R., Deinhardt F. Hepatitis B vaccination: how long does protection last? Lancet. ii:1994;458.
8. Jilg W., Schmidt M., Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol. 6:1988;201-207.
9. Hadler S.C., Francis D.P., Maynard J.E.et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 315:1986;209-214.
10. Jilg W., Schmidt M., Deinhart F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 17:1989;70-76.
11. Davidson M., Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 13(suppl A):1986;31-38.
12. Jilg W., Schmidt M., Deinhardt F. Immune response to hepatitis B revaccination. J Med Virol. 24:1988;377-384.
13. Wismans P.J., Van Hattum J., Mudde G.C., Endeman H.J., Poel J., de Gast G.C. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol. 8:1989;236-240.
14. Beasley R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer. 61:1988;1942-1956.
15. Beasley R.P., Hwang L.Y. Overview on the epidemiology of hepatocellular carcinoma. Hollinger F.B., Lemon S.M., Margolis H. Viral hepatitis and liver disease. 1991;532-535 Williams & Wilkins, Baltimore.
16. Romero R., Lavine J.E. Viral hepatitis in children. Semin Liver Dis. 14:1994;289-302.
17. Lieming D., Mintai Z., Yinfu W., Shaochon Z., Weiqin K., Smego R.A. Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis. 17:1993;475-479.
18. Lee P.-I. Lee, C-Y. , Huang, L-M., Chang, M-H. Long-term efficacy of recombinant hepatitis B vaccine and risk of infection in infants born to mothers with hepatitis B e antigen. Pediatrics. 126:1995;716-721.
19. Crovari P., Cuneo-Crovari P., Icardi G.C., Bonanni P., Coppola R.C. Immunization of young adults with two yeast-derived hepatitis B vaccines. Zuckerman A.J. Viral hepatitis and liver disease: proceedings of International Symposium on Viral Hepatitis and Liver Disease (London, May 26-28, 1987). 1988;1071-1073 Alan R Liss, New York.
20. e Congresso Nazionale d'Igiene (21-24 Oct, 1992, Montecatini Terme, Italy). 1992;116-119.
21. Treadwell T.L., Keeffe E.B., Lake J.et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med. 95:1993;584-588.
22. Zanetti A.R., Tanzi E., Romano L.et al. Kinetics of antibody response to hepatitis B virus determinants and to recombinant vaccines in Italy. J Med Virol. 32:1990;219-224.
23. Van Hattum J., Maikoe T., Poel J., de Gast G.C. In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccination who lost anti-HBs. Hollinger F.B.et al. Viral hepatitis and liver disease. 1992;774-776 Williams & Wilkins, Baltimore.
24. Boland G.J., de Gast G.C., Italiander E., van der Reijden J., van Hattum L. Long-term immunity to hepatitis B infection after vaccination with recombinant hepatitis B vaccine. Hepatology. 22:1995;325.
25. Leroux-Roels G., Van Hecke E., Michielson W., Voet P., Hauser P., Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunisation with hepatitis B surface antigen (HBsAg) vaccines. Vaccine. 12:1994;812-818.
26. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: results of a 10-year study. J Infect Dis. 175:1997;674-677.
27. Chiaramonte M., Ngatchu T., Majori S.et al. Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunisation. Scand J Gastroenterol. 30:1995;601-603.
28. Hadler S.C., Coleman P.J., O'Malley P., Judson F.N., Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. Hollinger F.B., Lemon S.M., Margolis H.S. Viral hepatitis and liver disease. 1991;766-768 Williams & Wilkins, Baltimore.
29. Stevens C.E., Taylor P.E., Tong M.J., Toy P.T., Vyas G.N. Hepatitis B vaccine: an overview. Eds Vyas G.N., Dienstag J.L., Hoofnagle J.H. Viral hepatitis and liver disease. 1984;275-291 Grune and Stratton, Orlando.
30. Zuckerman J.N., Zuckerman A.J. Is there a need for boosters of hepatitis B vaccines? Viral Hepatitis Rev. 4:1998;43-46.
31. West D.J., Watson B., Lichtman J., Hesley T.M., Hedberg K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Ped Infect Dis J. 13:1994;745-747.
32. Liao S., Li R., Li H.et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 17:1999;2661-2666.
33. Grob P. Hepatitis B vaccination of renal transplant and hemodialysis patients. Scand J Infect Dis Suppl. 38:1983;28-32.
34. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal child vaccination. Recommendations of the Immunisation Practices Advisory Committee. MMWR. 40:1991;1-25.
35. van Ditzhuijsen T.J., de Witte-van der Schoot E., van Loon A.M., Rijntjes P.J., Yap S.H. Hepatitis B virus infection in an institution for the mentally retarded. Am J Epidemiol. 128:1988;629-638.
36. Williamson H.G., Lehmann N.I., Dimitrakakis M., Sharma D.L., Gust I.D. A longitudinal study of hepatitis infection in an institution for the mentally retarded. Aust N Z J Med. 12:1982;1.
37. Vellinga A., Van Damme P., Bruckers L., Weyler J.J., Molenberghs G., Meheus A. Modelling long-term persistence of hepatitis B antibodies after vaccination. J Med Virol. 57:1999;100-103.
38. Vellinga A., Van Damme P., Weyler J.J., Vranckx R., Meheus A. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 17:1999;602-606.